Owkin, a French-American biotechnology company that applies artificial intelligence (AI) to drug discovery, development, and diagnostics, announced that it has entered into a collaboration agreement with MSD, the trade name of Merck & Co Inc., Rahway NJ USA to develop and commercialize AI-powered digital pathology diagnostics for the EU...
Anagenex and Nimbus Therapeutics (Nimbus) announced they have initiated a research collaboration. Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI), will work closely with Nimbus to discover small molecule drugs for multiple challenging targets.
Through this multi-target collaboration, the companies will apply Anagenex’s...
Expanded Workflow Solutions and Targeted Consulting Services Help Enterprise Customers Quickly Maximize the Value of Technology Investments from Komodo and Beyond
Komodo Health announces the expansion of its enterprise engagement capabilities and launches a new, dedicated Enterprise Strategy and Transformation team. As data, technology, and AI continue to accelerate breakthrough...
Atomic AI’s ATOM-1 large language model (LLM) demonstrates state-of-the-art accuracy for predicting RNA structure and function
Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, announced that the Company has created the first large language model (LLM) leveraging chemical mapping data....
Life science data can be highly disjointed and complex yet rich in potential insights. There are a variety of common insight-generation activities carried out with functional groups and through different channels; however, the findings are often disjointed and rarely connected.
Consequently, insights are frequently missed in all the information noise....
HeartBeam, Inc., a medical technology company focused on transforming cardiac care through the power of personalized insights, announced significant developments for the use of artificial intelligence (AI) applied to its proprietary vectorelectrocardiography (VECG) technology, including the addition of new leadership and advisory roles. By coupling machine learning methods with...
NavaX will revolutionize the end-to-end Research and Development processes with the latest advanced technologies
ArisGlobal, a market leader in Life Sciences technology and the creator of LifeSphere®, has launched LifeSphere NavaX, a cutting-edge cognitive computing engine to expedite R&D IT Digitization by leveraging advanced technologies including Large Language Models (LLM)...
Inductive Bio, a technology company developing a machine learning (ML) platform designed to dramatically accelerate the compound optimization process, emerged from stealth with $4.3M in funding. Their seed round was co-led by Andreessen Horowitz (a16z) Bio + Health and Lux Capital, with participation from Character, Bessemer Venture Partners, Alleycorp, and...
CHARM Therapeutics , a 3D deep learning biotechnology company dedicated to the discovery and development of transformational medicines, announced the appointments of Sarah Skerratt, Ph.D. announced as Chief Scientific Officer (CSO) and Laura Hare as Chief People Officer and Head of Business Operations.
“These leadership team updates mark a transition...
Bristol Myers Squibb announced the first disclosure of primary analysis results from the high-risk, second-line cohort of TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi® (lisocabtagene maraleucel, liso-cel) in patients with relapsed or refractory follicular lymphoma (FL) (Oral Presentation #602). TRANSCEND FL is the largest clinical trial to...
